Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

AstraZeneca Signs $150 Million China Deal with Ironwood Pharma

publication date: Oct 23, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
AstraZeneca signed a $150 million deal with Ironwood Pharmaceuticals to co-develop and co-commercialize Ironwood's novel constipation treatment in China. Linaclotide, a guanylate cyclase-C (GC-C) agonist, was approved by the US FDA in August to treat chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. In May, Ironwood announced a Phase III trial of the drug in China. More details....

Stock Symbols: (NYSE: AZN) (NSDQ: IRWD)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners